 | • レポートコード：MRC2312MG07370 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、129ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の小児てんかん市場規模と予測を収録しています。・世界の小児てんかん市場：売上、2018年-2023年、2024年-2029年 ・世界の小児てんかん市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の小児てんかん市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「シナプス抑制」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 小児てんかんのグローバル主要企業は、UCB Pharma、 AbbVie、 Mylan、 Zydus Pharms USA、 Aurobindo Pharma、 Dr Reddys Labs、 LUPIN、 Orchid、 Sun Pharm、 Teva、 Novartis、 Pfizer、 Eisai、 Humanwell、 Apotex Corporation、 Biomed Pharma、 Nucare Pharmaceuticals、 Taro Pharmaceuticalsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、小児てんかんのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の小児てんかん市場：タイプ別、2018年-2023年、2024年-2029年 世界の小児てんかん市場：タイプ別市場シェア、2022年 ・シナプス抑制、電位依存性イオンチャネル調節、シナプス抑制強化 世界の小児てんかん市場：用途別、2018年-2023年、2024年-2029年 世界の小児てんかん市場：用途別市場シェア、2022年 ・赤ちゃん、子供、青少年 世界の小児てんかん市場：地域・国別、2018年-2023年、2024年-2029年 世界の小児てんかん市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における小児てんかんのグローバル売上、2018年-2023年 ・主要企業における小児てんかんのグローバル売上シェア、2022年 ・主要企業における小児てんかんのグローバル販売量、2018年-2023年 ・主要企業における小児てんかんのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 UCB Pharma、 AbbVie、 Mylan、 Zydus Pharms USA、 Aurobindo Pharma、 Dr Reddys Labs、 LUPIN、 Orchid、 Sun Pharm、 Teva、 Novartis、 Pfizer、 Eisai、 Humanwell、 Apotex Corporation、 Biomed Pharma、 Nucare Pharmaceuticals、 Taro Pharmaceuticals ************************************************************* ・調査・分析レポートの概要 小児てんかん市場の定義 市場セグメント 世界の小児てんかん市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の小児てんかん市場規模 世界の小児てんかん市場規模：2022年 VS 2029年 世界の小児てんかん市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの小児てんかんの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の小児てんかん製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：シナプス抑制、電位依存性イオンチャネル調節、シナプス抑制強化 小児てんかんのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：赤ちゃん、子供、青少年 小児てんかんの用途別グローバル売上・予測 ・地域別市場分析 地域別小児てんかん市場規模 2022年と2029年 地域別小児てんかん売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） UCB Pharma、 AbbVie、 Mylan、 Zydus Pharms USA、 Aurobindo Pharma、 Dr Reddys Labs、 LUPIN、 Orchid、 Sun Pharm、 Teva、 Novartis、 Pfizer、 Eisai、 Humanwell、 Apotex Corporation、 Biomed Pharma、 Nucare Pharmaceuticals、 Taro Pharmaceuticals ... |
This research report provides a comprehensive analysis of the Epilepsy in Children market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Epilepsy in Children market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Epilepsy in Children, challenges faced by the industry, and potential opportunities for market players.
The global Epilepsy in Children market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Epilepsy in Children market presents opportunities for various stakeholders, including Baby, Child. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Epilepsy in Children market. Additionally, the growing consumer demand present avenues for market expansion.
The global Epilepsy in Children market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Epilepsy in Children market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Epilepsy in Children market.
Market Overview: The report provides a comprehensive overview of the Epilepsy in Children market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Inhibit Synaptic Excitation, Regulates Voltage-gated ion Channels), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Epilepsy in Children market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Epilepsy in Children market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Epilepsy in Children market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Epilepsy in Children market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Epilepsy in Children market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Epilepsy in Children market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Epilepsy in Children, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Epilepsy in Children market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Epilepsy in Children market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Inhibit Synaptic Excitation
Regulates Voltage-gated ion Channels
Enhance Synaptic Depression
Market segment by Application
Baby
Child
Teenager
Global Epilepsy in Children Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
UCB Pharma
AbbVie
Mylan
Zydus Pharms USA
Aurobindo Pharma
Dr Reddys Labs
LUPIN
Orchid
Sun Pharm
Teva
Novartis
Pfizer
Eisai
Humanwell
Apotex Corporation
Biomed Pharma
Nucare Pharmaceuticals
Taro Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Epilepsy in Children, market overview.
Chapter 2: Global Epilepsy in Children market size in revenue.
Chapter 3: Detailed analysis of Epilepsy in Children company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Epilepsy in Children in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Epilepsy in Children Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Epilepsy in Children Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Epilepsy in Children Overall Market Size
2.1 Global Epilepsy in Children Market Size: 2022 VS 2029
2.2 Global Epilepsy in Children Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Epilepsy in Children Players in Global Market
3.2 Top Global Epilepsy in Children Companies Ranked by Revenue
3.3 Global Epilepsy in Children Revenue by Companies
3.4 Top 3 and Top 5 Epilepsy in Children Companies in Global Market, by Revenue in 2022
3.5 Global Companies Epilepsy in Children Product Type
3.6 Tier 1, Tier 2 and Tier 3 Epilepsy in Children Players in Global Market
3.6.1 List of Global Tier 1 Epilepsy in Children Companies
3.6.2 List of Global Tier 2 and Tier 3 Epilepsy in Children Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Epilepsy in Children Market Size Markets, 2022 & 2029
4.1.2 Inhibit Synaptic Excitation
4.1.3 Regulates Voltage-gated ion Channels
4.1.4 Enhance Synaptic Depression
4.2 By Type – Global Epilepsy in Children Revenue & Forecasts
4.2.1 By Type – Global Epilepsy in Children Revenue, 2018-2023
4.2.2 By Type – Global Epilepsy in Children Revenue, 2024-2029
4.2.3 By Type – Global Epilepsy in Children Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Epilepsy in Children Market Size, 2022 & 2029
5.1.2 Baby
5.1.3 Child
5.1.4 Teenager
5.2 By Application – Global Epilepsy in Children Revenue & Forecasts
5.2.1 By Application – Global Epilepsy in Children Revenue, 2018-2023
5.2.2 By Application – Global Epilepsy in Children Revenue, 2024-2029
5.2.3 By Application – Global Epilepsy in Children Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Epilepsy in Children Market Size, 2022 & 2029
6.2 By Region – Global Epilepsy in Children Revenue & Forecasts
6.2.1 By Region – Global Epilepsy in Children Revenue, 2018-2023
6.2.2 By Region – Global Epilepsy in Children Revenue, 2024-2029
6.2.3 By Region – Global Epilepsy in Children Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Epilepsy in Children Revenue, 2018-2029
6.3.2 US Epilepsy in Children Market Size, 2018-2029
6.3.3 Canada Epilepsy in Children Market Size, 2018-2029
6.3.4 Mexico Epilepsy in Children Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Epilepsy in Children Revenue, 2018-2029
6.4.2 Germany Epilepsy in Children Market Size, 2018-2029
6.4.3 France Epilepsy in Children Market Size, 2018-2029
6.4.4 U.K. Epilepsy in Children Market Size, 2018-2029
6.4.5 Italy Epilepsy in Children Market Size, 2018-2029
6.4.6 Russia Epilepsy in Children Market Size, 2018-2029
6.4.7 Nordic Countries Epilepsy in Children Market Size, 2018-2029
6.4.8 Benelux Epilepsy in Children Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Epilepsy in Children Revenue, 2018-2029
6.5.2 China Epilepsy in Children Market Size, 2018-2029
6.5.3 Japan Epilepsy in Children Market Size, 2018-2029
6.5.4 South Korea Epilepsy in Children Market Size, 2018-2029
6.5.5 Southeast Asia Epilepsy in Children Market Size, 2018-2029
6.5.6 India Epilepsy in Children Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Epilepsy in Children Revenue, 2018-2029
6.6.2 Brazil Epilepsy in Children Market Size, 2018-2029
6.6.3 Argentina Epilepsy in Children Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Epilepsy in Children Revenue, 2018-2029
6.7.2 Turkey Epilepsy in Children Market Size, 2018-2029
6.7.3 Israel Epilepsy in Children Market Size, 2018-2029
6.7.4 Saudi Arabia Epilepsy in Children Market Size, 2018-2029
6.7.5 UAE Epilepsy in Children Market Size, 2018-2029
7 Epilepsy in Children Companies Profiles
7.1 UCB Pharma
7.1.1 UCB Pharma Company Summary
7.1.2 UCB Pharma Business Overview
7.1.3 UCB Pharma Epilepsy in Children Major Product Offerings
7.1.4 UCB Pharma Epilepsy in Children Revenue in Global Market (2018-2023)
7.1.5 UCB Pharma Key News & Latest Developments
7.2 AbbVie
7.2.1 AbbVie Company Summary
7.2.2 AbbVie Business Overview
7.2.3 AbbVie Epilepsy in Children Major Product Offerings
7.2.4 AbbVie Epilepsy in Children Revenue in Global Market (2018-2023)
7.2.5 AbbVie Key News & Latest Developments
7.3 Mylan
7.3.1 Mylan Company Summary
7.3.2 Mylan Business Overview
7.3.3 Mylan Epilepsy in Children Major Product Offerings
7.3.4 Mylan Epilepsy in Children Revenue in Global Market (2018-2023)
7.3.5 Mylan Key News & Latest Developments
7.4 Zydus Pharms USA
7.4.1 Zydus Pharms USA Company Summary
7.4.2 Zydus Pharms USA Business Overview
7.4.3 Zydus Pharms USA Epilepsy in Children Major Product Offerings
7.4.4 Zydus Pharms USA Epilepsy in Children Revenue in Global Market (2018-2023)
7.4.5 Zydus Pharms USA Key News & Latest Developments
7.5 Aurobindo Pharma
7.5.1 Aurobindo Pharma Company Summary
7.5.2 Aurobindo Pharma Business Overview
7.5.3 Aurobindo Pharma Epilepsy in Children Major Product Offerings
7.5.4 Aurobindo Pharma Epilepsy in Children Revenue in Global Market (2018-2023)
7.5.5 Aurobindo Pharma Key News & Latest Developments
7.6 Dr Reddys Labs
7.6.1 Dr Reddys Labs Company Summary
7.6.2 Dr Reddys Labs Business Overview
7.6.3 Dr Reddys Labs Epilepsy in Children Major Product Offerings
7.6.4 Dr Reddys Labs Epilepsy in Children Revenue in Global Market (2018-2023)
7.6.5 Dr Reddys Labs Key News & Latest Developments
7.7 LUPIN
7.7.1 LUPIN Company Summary
7.7.2 LUPIN Business Overview
7.7.3 LUPIN Epilepsy in Children Major Product Offerings
7.7.4 LUPIN Epilepsy in Children Revenue in Global Market (2018-2023)
7.7.5 LUPIN Key News & Latest Developments
7.8 Orchid
7.8.1 Orchid Company Summary
7.8.2 Orchid Business Overview
7.8.3 Orchid Epilepsy in Children Major Product Offerings
7.8.4 Orchid Epilepsy in Children Revenue in Global Market (2018-2023)
7.8.5 Orchid Key News & Latest Developments
7.9 Sun Pharm
7.9.1 Sun Pharm Company Summary
7.9.2 Sun Pharm Business Overview
7.9.3 Sun Pharm Epilepsy in Children Major Product Offerings
7.9.4 Sun Pharm Epilepsy in Children Revenue in Global Market (2018-2023)
7.9.5 Sun Pharm Key News & Latest Developments
7.10 Teva
7.10.1 Teva Company Summary
7.10.2 Teva Business Overview
7.10.3 Teva Epilepsy in Children Major Product Offerings
7.10.4 Teva Epilepsy in Children Revenue in Global Market (2018-2023)
7.10.5 Teva Key News & Latest Developments
7.11 Novartis
7.11.1 Novartis Company Summary
7.11.2 Novartis Business Overview
7.11.3 Novartis Epilepsy in Children Major Product Offerings
7.11.4 Novartis Epilepsy in Children Revenue in Global Market (2018-2023)
7.11.5 Novartis Key News & Latest Developments
7.12 Pfizer
7.12.1 Pfizer Company Summary
7.12.2 Pfizer Business Overview
7.12.3 Pfizer Epilepsy in Children Major Product Offerings
7.12.4 Pfizer Epilepsy in Children Revenue in Global Market (2018-2023)
7.12.5 Pfizer Key News & Latest Developments
7.13 Eisai
7.13.1 Eisai Company Summary
7.13.2 Eisai Business Overview
7.13.3 Eisai Epilepsy in Children Major Product Offerings
7.13.4 Eisai Epilepsy in Children Revenue in Global Market (2018-2023)
7.13.5 Eisai Key News & Latest Developments
7.14 Humanwell
7.14.1 Humanwell Company Summary
7.14.2 Humanwell Business Overview
7.14.3 Humanwell Epilepsy in Children Major Product Offerings
7.14.4 Humanwell Epilepsy in Children Revenue in Global Market (2018-2023)
7.14.5 Humanwell Key News & Latest Developments
7.15 Apotex Corporation
7.15.1 Apotex Corporation Company Summary
7.15.2 Apotex Corporation Business Overview
7.15.3 Apotex Corporation Epilepsy in Children Major Product Offerings
7.15.4 Apotex Corporation Epilepsy in Children Revenue in Global Market (2018-2023)
7.15.5 Apotex Corporation Key News & Latest Developments
7.16 Biomed Pharma
7.16.1 Biomed Pharma Company Summary
7.16.2 Biomed Pharma Business Overview
7.16.3 Biomed Pharma Epilepsy in Children Major Product Offerings
7.16.4 Biomed Pharma Epilepsy in Children Revenue in Global Market (2018-2023)
7.16.5 Biomed Pharma Key News & Latest Developments
7.17 Nucare Pharmaceuticals
7.17.1 Nucare Pharmaceuticals Company Summary
7.17.2 Nucare Pharmaceuticals Business Overview
7.17.3 Nucare Pharmaceuticals Epilepsy in Children Major Product Offerings
7.17.4 Nucare Pharmaceuticals Epilepsy in Children Revenue in Global Market (2018-2023)
7.17.5 Nucare Pharmaceuticals Key News & Latest Developments
7.18 Taro Pharmaceuticals
7.18.1 Taro Pharmaceuticals Company Summary
7.18.2 Taro Pharmaceuticals Business Overview
7.18.3 Taro Pharmaceuticals Epilepsy in Children Major Product Offerings
7.18.4 Taro Pharmaceuticals Epilepsy in Children Revenue in Global Market (2018-2023)
7.18.5 Taro Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
